Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company

Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment

Fineline Cube Jan 12, 2024

Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...

Company Drug

Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management

Fineline Cube Jan 12, 2024

Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...

Company Drug

AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results

Fineline Cube Jan 12, 2024

AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...

Company

Changchun High & New Technology to Transfer 7.42% Stake to Ex-Wife in Divorce Settlement

Fineline Cube Jan 12, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has announced plans to transfer...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706

Fineline Cube Jan 12, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...

Company Drug

Eisai’s Lemborexant Sleep Aid Lemborexant Filed for NMPA Approval in China

Fineline Cube Jan 12, 2024

The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523)...

Company

Astellas Pharma Appoints Zhao Ping as Chairman of China Operations

Fineline Cube Jan 12, 2024

Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed...

Company Deals

Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range

Fineline Cube Jan 12, 2024

Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen,...

Company Drug

Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study

Fineline Cube Jan 12, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that...

Company Deals

Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency

Fineline Cube Jan 12, 2024

Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has...

Company Drug

GSK Secures Second Indication Approval for Nucala in China for Severe Eosinophilic Asthma

Fineline Cube Jan 11, 2024

GSK plc (NYSE: GSK) has received approval for a second indication in China for its...

Company Deals

China Resources Medical Laboratory Partners with Qlife Lab for Comprehensive Mass Spectrometry Solutions

Fineline Cube Jan 11, 2024

China Resources Medical Holdings Company Limited’s subsidiary, China Resources (Guangdong) Medical Laboratory Co., Ltd, has...

Company Deals

WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal

Fineline Cube Jan 11, 2024

WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...

Company Deals

Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement

Fineline Cube Jan 11, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its...

Policy / Regulatory

China’s NHC Unveils Strategy to Enhance Pediatric Healthcare by 2025

Fineline Cube Jan 11, 2024

The National Health Commission (NHC) has issued a set of Opinions aimed at “Promoting the...

Company Deals

Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development

Fineline Cube Jan 11, 2024

Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for...

Company Drug

Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China

Fineline Cube Jan 11, 2024

Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA)...

Company

C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials

Fineline Cube Jan 11, 2024

C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...

Company

Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies

Fineline Cube Jan 11, 2024

Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...

Policy / Regulatory

Corruption Investigations Target Former HSA Officials in Guizhou and Hainan Amid Nationwide Crackdown

Fineline Cube Jan 11, 2024

Corruption investigations have been launched against former senior officials of the Healthcare Security Administration (HSA)...

Posts pagination

1 … 398 399 400 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.